Retirement Income Solutions Inc Has $334,000 Holdings in Amgen, Inc. (NASDAQ:AMGN)
Retirement Income Solutions Inc reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,812 shares of the medical research company’s stock after selling 200 shares during the quarter. Retirement Income Solutions Inc’s holdings in Amgen were worth $334,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the stock. Meyer Handelman Co. raised its stake in Amgen by 4.5% during the 2nd quarter. Meyer Handelman Co. now owns 117,123 shares of the medical research company’s stock valued at $21,583,000 after purchasing an additional 5,000 shares during the last quarter. Wealth Advisors of Tampa Bay LLC acquired a new position in Amgen during the 2nd quarter valued at $2,694,000. CHICAGO TRUST Co NA raised its stake in Amgen by 2.8% during the 2nd quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock valued at $685,000 after purchasing an additional 100 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Amgen by 0.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 92,244 shares of the medical research company’s stock valued at $16,996,000 after purchasing an additional 772 shares during the last quarter. Finally, Whittier Trust Co. raised its stake in Amgen by 1.3% during the 2nd quarter. Whittier Trust Co. now owns 33,957 shares of the medical research company’s stock valued at $6,257,000 after purchasing an additional 450 shares during the last quarter. Hedge funds and other institutional investors own 77.26% of the company’s stock.
Shares of AMGN stock traded up $1.23 during mid-day trading on Friday, reaching $175.34. The company’s stock had a trading volume of 3,070,426 shares, compared to its average volume of 2,407,805. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $210.19. The company has a market capitalization of $106.20 billion, a P/E ratio of 12.18, a P/E/G ratio of 2.13 and a beta of 1.16. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77. The firm’s 50-day moving average is $180.25.
In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total value of $351,360.00. Following the sale, the director now owns 16,219 shares of the company’s stock, valued at approximately $2,849,353.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 6,000 shares of company stock valued at $1,077,980. Corporate insiders own 0.25% of the company’s stock.
Several research firms recently commented on AMGN. Cantor Fitzgerald reiterated a “hold” rating and set a $41.00 target price on shares of Mylan in a research note on Monday, April 1st. Morgan Stanley set a $70.00 target price on shares of Edison International and gave the company a “hold” rating in a research note on Monday, July 15th. Zacks Investment Research upgraded shares of GreenTree Hospitality Group from a “sell” rating to a “hold” rating in a research note on Monday, April 15th. Oppenheimer set a $210.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $208.00.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.